📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Type 2 Diabetes Mellitus Treatment Market Analysis

ID: MRFR//4214-HCR | 85 Pages | Author: Rahul Gotadki| June 2024

Several factors shape the market dynamics of Type 2 Diabetes Mellitus (T2DM) treatment, reflecting the current changes in health care systems and technology as well as shifts in the patient populations. This has led to a high demand for effective drugs to prevent diabetes with T2DM being on the rise across the globe. The market is characterized by numerous drug interventions, life style modifications, and personalized medicine that are gaining popularity.

One driver of T2DM treatment market is an increasing incidence of diabetes globally. For instance, inactive way of living habits leads to poor dietary choices and a growing number of people struggle with obesity which result in increased prevalence of T2DM. As such, this surge in population has necessitated more research into development of new products that provide better solutions to this pandemic. Consequently, pharmaceutical companies are striving to develop drugs that not only control blood glucose levels but also address complications hence expanding the potentiality of growth as a market.

Market dynamics are shaped by technological advancements too. Continuous glucose monitoring systems, smart insulin pens and digital health platforms have been introduced to enhance self-management among patients. Apart from their convenience advantages, they are also essential for promoting compliance rate something which is very critical in T2DM management. Moreover AI integration alongside machine learning in diabetes care underscores personalization and precision trends in therapy.

The competition among pharmaceutical firms for superiority can be termed as fierce in terms of their fight for supremacy regarding type 2 diabetes mellitus (T2DM) treatment landscape. Patent cliffs associated with major brands have allowed generics into play thus creating room for competition within this industry hence assuring affordable choices thereby leading to reduced costs on patients’ part most often procurable through insurance policies coverage options. Moreover strategic collaborations including mergers and acquisitions have become more prevalent where businesses aim at reinforcing their stocks while getting access to other markets.

Government initiatives plus healthcare policies significantly affect market dynamics too. Therefore governments around the globe have intensified measures in relation to prevention, early diagnosis and efficient management as they become more aware of the economic burden of diabetes on health systems. This leads to healthcare investment in terms of infrastructure, educational campaigns and research hence an enabling environment for growth is created.

Patient preferences and demands have changed with a growing inclination towards holistic and integrative approaches in the management of diabetes. As such, this has created a market for complementary therapies, nutritional supplements and lifestyle interventions. In response to this trend, healthcare providers now focus on offering all-rounded solutions that overcome traditional pharmacological interventions.

There are still some problems in type 2 diabetes mellitus (T2DM) treatment market such as scanty access to health care especially in underdeveloped areas, high costs related with advanced technologies and requirement of better patient education among others. Nevertheless these challenges also present opportunities for innovation as well as collaboration within the ecosystem of healthcare.”

Type 2 Diabetes Mellitus Treatment Market Scenario:

The Type 2 Diabetes Mellitus Treatment Market is expected to reach USD 39,673 Million by 2030 at 9.2% CAGR during the forecast period 2022-2030. Type 2 diabetes mellitus is a metabolic disorder which results from an excess of caloric intake over energy expenditure. The condition is characterized by progressive insulin secretory defect, which increases the body’s demand for insulin in order to retain glucose homeostasis. Hyperglycemia is a major symptom of type 2 diabetes mellitus. According to the National Diabetes Statistics Report suggested by CDC, it is found that 9.4% of the U.S. population, i.e. 30.3 million people had diabetes in 2015.

It is noted that rising technological advancements and escalating prevalence are the key factors driving the type 2 diabetes mellitus treatment market. With the rising awareness about the condition, market players are coming up with novel drugs and devices owing to technological advancements. For instance, in December 2017, Novo Nordisk received FDA approval for Ozempic (semaglutide). The drug was specially designed for the treatment of type 2 diabetes mellitus. In the same year, Merck has also received FDA approval for Steglatro (ertugliflozin).

Various other factors such as growing awareness, huge research funding in diabetes diagnosis and treatment, unmet medical needs, increasing global prevalence of obesity, improving regulatory framework, increasing government assistance, and increasing adoption rate, are continuously contributing to the growth of the global type 2 diabetes mellitus treatment market.

Despite these drivers, there are some issues associated with type 2 diabetes mellitus treatment market. The high cost associated with diagnosis and treatment of diabetes, side effects of available treatment options, and poor healthcare system in low and middle-income countries may hamper the growth of the market to an extent.

A chronic condition that affects the body's blood sugar level is type 2 diabetes (T2D). The cardiovascular system, blood vessels, kidneys, eyes, and nerves suffer negative effects from hyperglycemia or elevated blood sugar levels. The market for diabetes treatments has been paved for expansion by the rising prevalence of the disease and advancements in novel diabetes therapies, which have considerably improved the market's design and functioning. A metabolic disease called type 2 diabetes mellitus is brought on by a calorie surplus compared to energy expenditure. The increasing insulin secretory failure that characterizes the syndrome raises the body's need for insulin to maintain glucose homeostasis. One of the main signs of type 2 diabetes mellitus is hyperglycemia. The diabetes therapy market has been growing steadily due to several factors.

First, the market has been driven by an increase in healthcare spending. Additionally, the market for diabetic treatments is impacted by the growing elderly population. The need for diabetic therapies has been fueled by growing awareness of diabetes and its effects. Early diagnosis, improved management techniques, and a rise in demand for efficient treatment alternatives have all been made possible by education campaigns and efforts launched by medical organizations, governments, and advocacy for patients' organizations. Governments worldwide are implementing plans to fight diabetes and its associated issues. Campaigns to raise awareness, early screening applications, reimbursement rules, and financial incentives to create and adopt novel therapies are just a few of these activities. The increase in the prevalence of type 2 diabetes (T2D) disease worldwide is the main reason driving the growth of the T2D market globally.

The market for products, drugs, equipment, and treatments used for managing and treating diabetes is a worldwide diabetes treatment market. Due to the body's inability to efficiently generate or use the hormone insulin, which controls blood glucose levels, diabetes is a persistent medical illness marked by excessive blood sugar levels. However, the market expansion is constrained by patients' lack of knowledge about the accessible nature of such treatments. On the other hand, unmet medical demands in developing nations are anticipated to offer profitable market expansion potential.

The US Food and Drug Administration has authorized Bexagliflozin (Brenzavvy, TheracosBio) to receive treatment for adult patients with type 2 diabetes. For people with type 2 diabetes, but not those with type 1 diabetes, the once-daily 20-mg oral sodium-glucose cotransporter 2 (SGLT2) inhibitor is suggested as an addition to diet and exercise to enhance glycemic control. Adults having a glomerular filtration rate that has been estimated can utilize it. Bexagliflozin, either as a monotherapy or as an addition to metformin and other glucose-lowering medications and combinations, significantly decreased A1c and fasting blood glucose at twenty-four weeks in the phase 3 studies. Additionally, it led to moderate drops in systolic blood pressure and body weight.


The global type 2 diabetes mellitus treatment market is segmented on the basis of treatment and end user.

On the basis of the treatment, the market is classified as a drug class and devices. The drug class is further segmented into insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, secretagogues, peptide analogs, others. The sub-segment of sensitizers includes thiazolidinediones and biguanides. The sub-segment of secretagogues includes sulfonylureas and non-sulfonylureas. The devices market is further segmented into blood glucose monitoring devices and insulin delivery devices. The sub-segment of blood glucose monitoring devices includes testing strips, lancets, continuous glucose monitors, self-monitoring blood glucose meters, and others. The sub-segment of insulin delivery devices includes insulin pens, insulin pumps, insulin syringes, and insulin jet injectors.

On the basis of the end user, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.


The treatment of type 2 diabetes in children 10 years of age and older has been approved by the US Food and Drug Administration for both empagliflozin (Jardiance, Boehringer Ingelheim) or empagliflozin coupled with metformin (Synjardy, BI). After metformin, which seems less successful for youngsters than adults, its approval offers an additional oral treatment choice for kids and teens with type 2 diabetes. For children with type 2 diabetes, injectable glucagon-like peptide-1 (GLP-1) agonists are also available. These include once-weekly extended-release exenatide (Bydureon/Bydureon BCise) and daily liraglutide (Victoza).

Regional Analysis

The Americas dominate the type 2 diabetes mellitus treatment market owing to the presence of patient population, a well-developed technology, high healthcare expenditure, and the presence of the leading players. Due to the rising prevalence of diabetes, various companies, and government associations are actively participating in improving diabetes care. For instance, The Merck Foundation has provided funding of around USD 10,000,000 for the projects designed to improve diabetes care in the United States.

Europe holds the second position in the type 2 diabetes mellitus treatment market. It is expected that the government support towards research & development expenditure and amendments in reimbursement policies in the healthcare is likely to drive the European market. As per the German maternity guidelines, every pregnant woman can undergo glucose challenge test for the early diagnosis of Gestational diabetes mellitus, and the charges for the test are completely covered by women’s health insurance.

Asia Pacific is the fastest growing type 2 diabetes mellitus treatment market owing to a huge patient pool, increasing demand, and development in healthcare technology.

The Middle East & Africa holds the lowest share of the global market due to low development, lack of technical knowledge, and poor medical facilities.

Key Players

Some of key the players in the global type 2 diabetes mellitus treatment market are Abbott Laboratories, Acon Laboratories, Inc., Adocia, Akros Pharma, Amgen, AstraZeneca, Bayer AG, Becton, Dickinson and Company, Biocon, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck, Novartis & Co., Novo Nordisk, Peptron, Pfizer, Roche Diagnostics Ltd., Sanofi, Sunpharma, Takeda Pharmaceuticals, and others.

Intended Audience

  • Pharmaceutical Companies

  • Medical Device Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.